ERBB2 and gastric cancer: In terms of HER2+ blockade for LAGC, the PETRARCA trial studied the effect of perioperative trastuzumab, pertuzumab, and FLOT compared to FLOT alone in patients with cT2-4 and/or N+ GC/GEJC and HER2+ overexpression [101].